Cigna settles FTC insulin case, commits to overhauling drug pricing

In this article

Cigna Corp’s

Express Scripts has settled the U.S. Federal Trade Commission’s claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies, according to a copy of the settlement seen by Reuters.

The Trump administration has taken aim at high drug costs, and secured agreements with pharmaceutical companies to slash prices. The settlement fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna’s Express Scripts, UnitedHealth Group Inc’s

Optum unit and CVS Health Corp’s